<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00606723</url>
  </required_header>
  <id_info>
    <org_study_id>AML SCT-BFM 2007</org_study_id>
    <secondary_id>2007-004517-34</secondary_id>
    <nct_id>NCT00606723</nct_id>
  </id_info>
  <brief_title>Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML</brief_title>
  <official_title>Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML; Multi Center Therapy Concept</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Clinical Trial Center GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Clinical Trial Center GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate whether stem cell transplantation from a matched sibling donor is equivalent
           to a matched unrelated donor in in a second complete remission of acute myeloid leukemia
           (AML).

        2. To evaluate whether stem cell transplantation (SCT) after chemotherapy (FLAMSA-schema)
           increases survival compared to a threshold derived from historical data

        3. To evaluate whether SCT from haploidentical donors for children having no matched donor
           will result in better survival with acceptable toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Target variables:

        -  Treatment response

        -  Event Free Survival

        -  Leukemia Free Survival

        -  Graft Versus Host Disease

        -  Regimen related toxicity
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate whether stem cell transplantation (SCT) from a matched sibling donor (MSD) is equivalent to a matched unrelated donor (MUD) in second complete remission (CR2).</measure>
    <time_frame>day 100</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate whether &quot;FLAMSA&quot; increases leukemia free survival (LFS) and overall survival (OS) as compared to a historic control group</measure>
    <time_frame>day 100</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate whether SCT from haploidentical donors for children having no matched donor will result in an acceptable toxicity profile and a better LFS as compared to historic controls.</measure>
    <time_frame>day 100</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prospective evaluation of event free survival (EFS), LFS, and OS after SCT from either a MSD or a MUD</measure>
    <time_frame>day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate whether it is feasible to standardize transplantation procedures in children with AML within the AML-Berlin/Frankfurt/Münster (BFM) study network</measure>
    <time_frame>day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of transplantation associated mortality by standardized donor selection criteria</measure>
    <time_frame>day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To further evaluate the contribution of immunomediated effects for the treatment of children suffering from very high risk AML</measure>
    <time_frame>day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prospective evaluation of late toxicities</measure>
    <time_frame>day 100 and year 5</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group I: Relapsed AML-patients with blast cell reduction to &lt;20% before the second course of induction therapy. These patients will receive conventional SCT.
Group II: Patients with non response to frontline treatment of AML, patients with blast cells &lt;20% before the second course of induction therapy who do not achieve a second remission and relapsed AML-patients with blast cells &gt;=20% before the second course of induction therapy. If these patients have a matched donor (MSD/MD) they will receive SCT with &quot;FLAMSA&quot;.
Group III: Patients who are eligible for Group II but have no matched donor. These patients will receive SCT from a haploidentical donor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hematopoietic stem cells from bone marrow or peripheral blood</intervention_name>
    <description>&gt; = 2 x 10*8 nucleated cells (WBC)/kg body weight of the recipient or rather &gt; = 4 x 10*6 nucleated CD34+ cells / kg body weight are required for engraftment. Suspension of stem cells is administered via intravenous infusion.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 0-21 years

          -  Patients suffering from either refractory de novo AML or relapsed AML or patients with
             very high risk AML in CR1

          -  In sexually active patients two reliable contraception methods are used. This includes
             every combination of a hormonal contraceptive (such as injection, transdermal patch,
             implant, cervical ring) or of an intrauterine device(IUD) with a barrier method (e.g.
             diaphragm, cervical cap, or condom) or with a spermicide.

          -  Written informed consent of patient, parents or legal guardians

        Exclusion Criteria:

          -  Severe renal impairment (GFR &lt; 30% predicted for age)

          -  Pregnant or lactating females

          -  Current participation in another clinical trial

          -  Patients ≥ 12 years old for Group 1 (&quot;BuCyMel&quot;) (patients younger that 12 years
             continue to be included)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Sauer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Graz University Hospital</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innsbruck University Hospital</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anna Children Hospital</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teaching Hospital Motol</name>
      <address>
        <city>Prag</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heidelberg University Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Erlangen-Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. von Haunersches Kinderspital</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regensburg University Hospital</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bavaria</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J.W. Goethe University Hospital and Faculty of Medicine</name>
      <address>
        <city>Frankfurt</city>
        <state>Hesse</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gießen University Hospital</name>
      <address>
        <city>Gießen</city>
        <state>Hesse</state>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School, Department of Paediatrics, Paediatric Hematology and Oncology</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Greifswald</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-West Pomerania</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Düsseldorf University Hospital</name>
      <address>
        <city>Düsseldorf</city>
        <state>North Rhine-Westphalia</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Münster University Hospital</name>
      <address>
        <city>Münster</city>
        <state>North Rhine-Westphalia</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Halle</name>
      <address>
        <city>Halle</city>
        <state>Saxony-Anhalt</state>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carl Gustav Carus University Children's Hospital Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Universitätskinderklinik und Poliklinik</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Jena</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <zip>07724</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Rudolf Virchow Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamburg-Eppendorf University Hospital</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2008</study_first_submitted>
  <study_first_submitted_qc>February 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2008</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed or refractory AML</keyword>
  <keyword>in children, adolescents and young adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

